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Neurofibromatosis type 1 (NF1) is a common neurodeve-
lopmentaldisordercausedby impaired functionof theneu-
rofibromin RAS regulator. Using a combination of Nf1
genetically engineered mice and pharmacological/genetic
inhibitionapproaches,wereport thatneurofibromindiffer-
entially controls neural stem cell (NSC) proliferation and
multilineage differentiation through the selective use of
the PI3K/AKT and RAF/MEK pathways. While PI3K/
AKT governs neurofibromin-regulated NSC proliferation,
multilineagedifferentiation isMEK-dependent.Moreover,
whereas MEK-regulated multilineage differentiation re-
quires Smad3-induced Jagged-1 expression andNotch acti-
vation, MEK/Smad3-regulated Hes1 induction is only
responsible for astrocyte andneuronal differentiation.Col-
lectively, these findings establishdistinct roles for theRAS
effector pathways in regulating brain NSC function.
Supplemental material is available for this article.
Received March 5, 2015; revised version accepted July 23, 2015.
Neurofibromatosis type1 (NF1) is acommonneurogenetic
disorder inwhich individualsmanifest numerousCNS ab-
normalities that reflect impaired neuronal and glial cell
lineage function. In this regard, 60%–80% of children
with NF1 exhibit impairments in learning, attention, and
memory (Diggs-Andrews and Gutmann 2013), and 15%–
20% of affected children develop low-grade astrocytomas
(gliomas) involving the optic pathway and brain stem
(Guillamo et al. 2003). The fact that both neuronal and
astroglial lineages are impacted raises the possibility that
theNF1 gene product neurofibromin is a critical regulator
of neural stem cell (NSC) growth and differentiation. Con-
sistent with this idea, previous reports have revealed that
neurofibromin negatively controls NSC proliferation and
self-renewal as well as multilineage differentiation (Hege-
dus et al. 2007; Lee et al. 2010) such thatNf1 inactivation
leads to increased numbers of spinal cord neuroglial pro-
genitors (Bennett et al. 2003) and increased telencephalic
NSCproliferation (Dasgupta andGutmann2005). Similar-
ly, conditionalNf1 gene inactivation inBLBP- orGFAP-ex-
pressing neuroglial progenitor cells results in increased
NSC proliferation and glial lineage differentiation in vivo
(Hegedus et al. 2007; Wang et al. 2012).
Neurofibromin is widely expressed in the developing
brain, where it primarily functions as a negative regulator
of RAS activity. Previous studies have demonstrated that
loss of neurofibromin expression in NSCs results in in-
creased proliferation and glial differentiation in a RAS-
and AKT-dependent fashion (Hegedus et al. 2007; Lee
et al. 2010). However, other studies have implicated
RAS/ERK signaling as the responsible pathway dictating
Nf1-deficient neural progenitor cell growth and differenti-
ation in the forebrain (Wang et al. 2012) and cerebellum
(Sanchez-Ortiz et al. 2014). Additionally, neurofibromin
control of mouse astrocyte and optic glioma growth is
mediated by both MEK and AKT effector arms through
convergence on the mammalian target of rapamycin
(mTOR) complex (Kaul et al. 2015). In contrast, neurofibro-
min regulation of human andmouse neuronal cyclic AMP
homeostasis is RAS-dependent but operates in a MEK/
AKT-independent manner through PKCζ (Anastasaki
and Gutmann 2014). Together, these observations argue
that neurofibromin regulation of nervous system cell biol-
ogy may be cell type- or cell function-specific.
To mechanistically define the signaling pathways
responsible for brain NSC function, we leveraged Nf1
genetically engineered mice and converging inhibition
strategies to demonstrate that neurofibromin regulation
of NSC proliferation and multilineage differentiation in-
volves the engagement of distinct RAS downstream sig-
naling pathways. Here, we establish that neurofibromin
control of NSC proliferation is PI3K/AKT-dependent,
while MEK/Smad3/Jagged1/Hes1-dependent signaling is
required for neurofibromin-regulated NSC glial and neu-
ronal differentiation in vitro and in vivo.
Results and Discussion
To determine which RAS downstream effectors were
hyperactivated following Nf1 inactivation, we focused on
third ventricle zone (TVZ) NSCs (Lee et al. 2012). Nf1−/−
and wild-type TVZ NSC cultures were generated from
postnatal day 1 (P1) Nf1flox/flox pups following Cre or
LacZ gene adenovirus infection, respectively. Following
neurofibromin loss, increased ERK (3.5-fold; Thr202/
Tyr204) and AKT (1.8-fold and threefold; Ser473 and
Thr308) phosphorylation was observed (Fig. 1A).
To identify which RAS effector pathway was responsi-
ble for neurofibromin regulationofNSCgrowthandmulti-
lineage differentiation, we used PI3K/AKT and MEK
pharmacological inhibitors. While MK2206 treatment in-
hibited AKT activation (Fig. 1B) and reduced Nf1−/− NSC
growth (Fig. 1C [direct cell counting], D [percentage of
Ki67+ cells]) to wild-type levels, it had no effect on ERK
phosphorylation (Fig. 1B). PD0325901 (PD901) treatment
inhibited MEK activation but did not decrease Nf1−/−
NSC proliferation (Fig. 1C) or AKT phosphorylation (Fig.
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1B). Similar results were obtained with additional PI3K
(NVP-BKM120 [BKM120]) and MEK (UO126) inhibitors
(Supplemental Fig. S1A,B). The observation that MEK in-
hibition had no effect on Nf1−/−NSC growth but reduced
Nf1−/− astrocyte proliferation (Kaul et al. 2015) further un-
derscores the importance of cell type specificity (Lee et al.
2012).
To determine whether differential RAS pathway con-
trol of NSC proliferation was also observed in vivo, we
used Nf1BLBP conditional knockout mice to inactivate
Nf1 gene expression in BLBP+ NSCs at embryonic day
9.5 (E9.5) (Hegedus et al. 2007). At P0.5, increased ERK
phosphorylation (Thr202/Tyr204), AKT phosphorylation
(Ser473 and Thr308), and proliferating cells (percentage
of Ki67+ cells) were observed in Nf1BLBP conditional
knockoutmice relative towild-type controls (Supplemen-
tal Fig. S1C,D). Following the treatment of pregnant fe-
males with either 5 mg/kg PD901 or 30 mg/kg BKM120
fromE15 to E18, the percentage of proliferating Ki67+ cells
within the TVZ was quantified at P0.5. ERK hyperactiva-
tion in theTVZofNf1BLBP conditional knockout pupswas
reduced by PD901 treatment; however, therewas no chan-
ge in TVZ cell proliferation (Fig. 1E). In contrast, BKM120
treatment inhibited AKT (Ser473 and Thr308 phosphory-
lation) hyperactivation and reduced TVZ cell proliferation
(Fig. 1E). Collectively, these data demonstrate that neuro-
fibromin regulates NSC proliferation in a PI3K/AKT-de-
pendent manner in vitro and in vivo, consistent with
previous findings (Lee et al. 2010).
AKT maintenance of NSC growth has been reported in
mice and flies (Lee et al. 2010, 2013; Amiri et al. 2012);
however, the role of AKT in regulating NSC multilineage
differentiation is less clear (Peltier et al. 2007). Following
in vitro differentiation,Nf1 loss in NSCs resulted in an in-
crease in the percentage of GFAP+ and O4+ cells (3.4-fold
and fourfold, respectively) and a decrease in Tuj1+ cells
(2.5-fold) relative to wild-type cells (Fig. 2A). While treat-
ment with the AKT inhibitor (MK2206) had no effect on
these Nf1-deficient NSC differentiation defects, MEK in-
hibition (PD901) restoredNf1−/−NSC astrocyte, oligoden-
drocyte (Olig2+ and O4+ cells), and neuron differentiation
to near wild-type levels (Fig. 2A; Supplemental Fig. S2A).
Similar results were observed using other PI3K (BKM120)
and MEK (UO126) inhibitors (Supplemental Fig. S2B).
To determine whether MEK activation was responsible
for these multilineage defects in vivo, Nf1BLBP conditional
knockout pups were treated from P0.5 to P18 (astrocytes
and oligodendrocytes) or from E15 to E18 (neurons and
Olig2+progenitors)withPD901orBKM120.WhileNf1 inac-
tivation in BLBP+ neural progenitor cells led to increased
numbers of GFAP+ astrocytes and APC+ oligodendrocytes
at P18 (Supplemental Fig. S2C), decreased numbers of
NeuN+ neurons and increased numbers of Olig2+ cells
were observed at P0.5 (Supplemental Fig. S2E). As observed
Figure 1. Neurofibromin regulates NSC proliferation in a PI3K/
AKT-dependent manner. (A) Nf1 loss in TVZ NSCs resulted in in-
creased ERK and AKT activation (pERKT202/Y204, pAKTS473, and
pAKTT308 phosphorylation) relative to wild-type controls. (B) Treat-
ment with the MEK (5 nM PD0325901 [PD901]) or AKT inhibitor
(50 nM MK2206) reduced ERK and AKT hyperactivation. Reduced
NSC numbers (direct cell counting) (C ) and percentage of Ki67+ cells
(D) were observed only inNf1−/−TVZNSCs treatedwithMK2206. (E)
NVP-BKM120 (BKM120) but not 5mg/kg PD901 treatment decreased
the percentage of Ki67+ cells in the TVZ of P18 Nf1BLBP conditional
knockoutmice in vivo (n = 4 per group) to nearlywild-type levels (dot-
ted line). ERK and AKT hyperactivation were decreased following
PD901 and BKM120 treatment, respectively, relative to wild-type
controls. n = 4 per group. (veh) Vehicle. Nuclei were counterstained
with DAPI. Error bars denote the mean ± SD. Bar, 100 μm. (∗) P <
0.05; (∗∗) P < 0.01.
Figure 2. Neurofibromin regulation of NSC multilineage differenti-
ation isMEK-dependent. (A) The astrocyte, oligodendrocyte, and neu-
ronal differentiation defects observed in Nf1−/− TVZ NSCs were
restored to wild-type (WT) levels following PD901, but not
MK2206, treatment. (B) PD901-treatedNf1BLBP conditional knockout
mice exhibited reduced astrocyte numbers compared with vehicle-
treated controls. n = 4 per group. No change in astrocyte numbers
were observed following BKM120 treatment. n = 4 per group. (C ) Den-
sitometric analyses of pERKT202/Y204, pAKTS473, and pAKTT308 im-
munoblots relative to total ERK and AKT levels. n = 4 per group.
Error bars denote the mean ± SD. (veh) Vehicle. Bar, 100 μm. (∗) P <
0.05; (∗∗) P < 0.01.
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in vitro,MEK, but not PI3K/AKT, inhibition restored astro-
cyte (Fig. 2B,C) and oligodendrocyte numbers in Nf1BLBP
conditional knockout mice to wild-type levels at P18 (Sup-
plemental Fig. S2D) as well as ameliorated the increase in
Olig2+cellsanddecrease inNeuN+cellsatP0.5(Supplemen-
tal Fig. S2E).Togetherwith the invitro results, thesedata re-
veal that AKT and MEK independently regulate NSC
proliferation andmultilineage differentiation, respectively.
The observation thatMEK is a central driver of gliogen-
esis is consistent with prior reports demonstrating that
Mek1/2-deficient mice exhibit impaired glial cell specifi-
cation (Li et al. 2012) and thatneonatalMEKinhibition res-
cues the developmental defects inNf1-deficient brains by
restoring normal neuron–glial specification (Wang et al.
2012). However, the mechanism responsible for neurofi-
bromin/MEK-driven multilineage differentiation has not
been elucidated. Two transcription factors, Erm and
Ascl1, can regulate gliogenesis in response to elevated
RAS/ERK signaling (Li et al. 2012; Breunig et al. 2015).
While Nf1−/− NSCs exhibit increased Erm expression by
quantitative RT–PCR (qRT–PCR) and Western blotting,
this was not attenuated following MEK inhibition
(PD901) (Supplemental Fig. S3A,B). In addition, no change
inAsc1protein levelswasobservedafterNf1 loss, andnear-
ly 100% of wild-type and Nf1−/− NSCs were Ascl1+ (Sup-
plemental Fig. S3B,C). Since Erm and Ascl1 function can
also be regulated by phosphorylation (Li et al. 2014), these
proteins could still play a role inNf1−/−NSC gliogenesis.
Based on increased Jagged-1 expression inNf1-deficient
mouse astrocytes (Banerjee et al. 2011) and numerous
studies highlighting the critical role of Notch1 signaling
in specifying neural cell fate during development (Lutolf
et al. 2002; Stump et al. 2002), we examined Jagged1/
Notch pathway activation. Following neurofibromin loss
inNSCs, therewas increased Jagged1 expressionandNotch
activation (Notch intracellular domain [NICD] expression)
in vitro (Fig. 3A) and in vivo (Fig. 3B). However, in contrast
to Nf1-deficient astrocytes (Banerjee et al. 2011), Jagged1
was not regulated by mTOR activation. While there was
a 2.1-fold and 3.6-fold increase in S6 Ser240/244 and
Ser235/236 phosphorylation, respectively, mTOR inhibi-
tionwith rapamycin did not affect Jagged1 orNICDexpres-
sion in Nf1−/− NSCs (Supplemental Fig. S3D). Consistent
with the hypothesis that neurofibromin control of Jagged1
in NSCs is AKT/mTOR-independent, MK2206 treatment
ofNf1−/−NSCs did not reduce Jagged1 orNICD expression
(Fig. 3C) or attenuate ERK hyperphosphorylation (Supple-
mental Fig. S3E). Instead,MEK inhibition (PD901) restored
Jagged1 and NICD expression inNf1−/−NSCs towild-type
levels (Fig. 3D) without any change in AKT phosphoryla-
tion (Supplemental Fig. S3F). Similar results were observed
with additional MEK (UO126) and PI3K (BKM120) inhibi-
tors (Supplemental Fig. S3G). Moreover, Jagged1 and
NICDexpression in theTVZofNf1BLBP conditional knock-
out mice was reduced following PD901 treatment (Fig. 3E)
but not by PI3K/AKT (BKM120) inhibition. Collectively,
these results establish that neurofibromin regulationof Jag-
ged1/Notch activation is mediated byMEK/ERK signaling
in vitro and in vivo.
The importance of Jagged1 to gliogenesis is further sup-
portedby studiesusing conditional Jagged1deletion in cer-
ebellar neuroepithelial cells (Weller et al. 2006) as well as
reports demonstrating that Jagged1-mediated Notch path-
way activation promotes astrogliogenesis in vivo (Hu et al.
2013) and inhibits neurogenesis in vitro (Wilhelmsson
et al. 2012). The ability of activatedNotch1 to dictatemul-
tilineage differentiation in neural progenitor cells typical-
ly involves the Hes1 and Hes5 transcription factors
(Furukawa et al. 2000; Hojo et al. 2000). Following Nf1
loss in NSCs, there was increased Hes1 and Hes5 expres-
sion (Fig. 4A), which was reduced by PD901 treatment
(Fig. 4B) in vitro. Moreover, ectopic expression of an acti-
vatedMEK (caMEK), but not an activated AKT (myrAKT),
molecule in NSCs increased Jagged1, NICD, Hes1, and
Hes5 levels (Supplemental Fig. S4A). Finally, MEK inhibi-
tion restoredHes1 andHes5 expression towild-type levels
in the TVZ of Nf1BLBP conditional knockout mice in vivo
(Fig. 4C). Together, these findings demonstrate that the
Notch1 signaling pathway is activated following neurofi-
bromin loss in a MEK-dependent manner.
Based on conflicting reports regarding Hes5 regulation
of gliogenesis (Hojo et al. 2000; Wu et al. 2003) and the
nearly exclusive expression of Hes1 within the TVZ, we
chose to focus onHes1. Using two independently generat-
edHes1 shRNA constructs to decrease Hes1 expression in
NSCs (60% reduction), the increased astrocyte differenti-
ation observed following neurofibromin loss was reduced
to near wild-type levels (Fig. 4D). Importantly, Hes1 re-
duction had no effect on Nf1−/− NSC growth (direct cell
counting) (Fig. 4E) or proliferation (percentage of Ki67+
cells) (Fig. 4F). Moreover, Hes1 knockdown ameliorated
Figure 3. Neurofibromin loss inNSCs results inMEK-dependent Jag-
ged1/Notch activation. Neurofibromin loss resulted in increased Jag-
ged1 and cleavedNotch1 (NICD) expression in vitro (A) and in vivo (B)
relative to controls. While MK2206 treatment did not reduce Jagged1
and NICD expression (C ), PD901 treatment reduced Nf1-deficient
NSC Jagged1 andNICD expression towild-type (WT) levels (D). (E) In-
creased Jagged1 and NICD expression was observed in the TVZ of
Nf1BLBP conditional knockout (CKO) mice, which was ameliorated
by PD901, but not BKM120, treatment. n = 4 per group. (veh) Vehicle.
NF1 controls neuroglial growth and differentiation
GENES & DEVELOPMENT 1679
 Cold Spring Harbor Laboratory Press on October 1, 2015 - Published by genesdev.cshlp.orgDownloaded from 
the decrease in neuronal differentiation in Nf1-deficient
NSCs but surprisingly had no effect on oligodendrocyte
differentiation (percentage of O4+ cells) (Supplemental
Fig. S4B). These findings demonstrate that neurofibromin
regulation of astrocyte and neuronal differentiation is me-
diated by Hes1 in a reciprocally coordinated fashion,
whereas other mechanisms underlie MEK-dependent oli-
godendrocyte differentiation. In this regard, Hes1 knock-
down did not reduce the number of Olig2+ cells
(Supplemental Fig. S4C). While RAF/MEK signaling is
an important determinant of oligodendrocyte differentia-
tion in mice (Galabova-Kovacs et al. 2008) and zebrafish
(Shin et al. 2012), other neurofibromin-regulated MEK
downstreampathways are likely responsible for governing
oligodendrocyte differentiation.
To determine how neurofibromin controls Jagged1 ex-
pression, we examined Jagged1 mRNA expression using
real-time qRT–PCR (Fig. 5A). Jagged-1mRNA expression
was regulated inNf1−/−NSCs on the transcriptional level
through MEK, since PD901 treatment restored Jagged1
mRNA to wild-type levels. Several potential regulators
of Jagged1 expression have been identified, including β-
catenin, YAP, and TGFβ/Smad3 (Chen et al. 2010; Zhang
et al. 2010; Tschaharganeh et al. 2013).While we observed
no changes in β-catenin activation or YAP expression fol-
lowing neurofibromin loss, the increased Smad3 expres-
sion observed in Nf1-deficient NSCs was reduced to
wild-type levels following PD901 treatment (Fig. 5B,C).
We next used genetic and pharmacologic approaches to
reduce Smad3 function. Following Smad3 knockdown (us-
ing two different shRNA constructs), Jagged1, NICD, and
Figure 4. Neurofibromin regulation ofNSC astrocyte differentiation
isHes1-dependent.Nf1 loss results in increasedexpressionof theHes1
andHes5Notchdownstreameffectors (A),whichwas restored towild-
type (WT) levels following5nMPD901 treatment (B). (C )Nf1BLBP con-
ditional knockout (CKO)mice treatedwith 5mg/kgPD901 (P0.5–P18)
have reduced Hes1 and Hes5 expression relative to vehicle-treated
mice. n = 4 per group. (D) Hes1 shRNA knockdown reduced the per-
centage GFAP+ astrocytes followingNf1−/−TVZNSC differentiation.
Hes1 knockdown (shHes1) did not reduce Nf1−/− TVZ NSC growth
(direct cell counting) (E) or proliferation (percentage of Ki67+ cells)
(F ). (veh) Vehicle. Error bars denote mean ± SD. Nuclei were counter-
stained with DAPI. Bar, 100 μm. (∗) P < 0.01; (N.S.) not significant.
Figure 5. Neurofibromin/Jagged1 regulation of astrocyte differentia-
tion requires MEK-mediated Smad3 expression. Increased Jagged1
transcription (A) and protein levels (B) in Nf1−/− NSCs were reduced
to wild-type levels following 5 nM PD901 treatment. PD901 treat-
ment of Nf1−/− NSCs had no effect on β-catenin activity or YAP ex-
pression but reduced Smad3 expression by Western blotting (B) and
immunocytochemistry (C ). (D) Smad3 knockdown restored Jagged1,
NICD, and Hes1, but not Hes5, expression to wild-type levels. (E)
The astrocyte, oligodendrocyte, and neuronal differentiation defects
observed in Nf1−/− TVZ NSCs were restored to near wild-type levels
following Smad3 knockdown. (F ) MEK inhibition (5 nM PD901) re-
ducedOlig2, but notOlig1, expression by qRT–PCRandWestern blot-
ting. Smad3 knockdown reduced Olig2 expression by Western
blotting (G) as well as the percentage of Olig2+ cells within the
Nf1−/− neurospheres (H). (I ) Proposed model of neurofibromin/RAS
regulationofNSCgrowth andmultilineage differentiation. (veh)Vehi-
cle. Error bars denotemean ± SD. Bar, 100 μm. (∗) P < 0.05; (∗∗) P < 0.01.
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Hes1 expression inNf1−/−NSCswas restored towild-type
levels (Fig. 5D). Similar to PD901 treatment, Smad3
knockdown of Nf1−/− NSCs restored astrocyte, oligoden-
drocyte, and neuronal differentiation to wild-type levels
(Fig. 5E). It should be noted that Smad3 knockdown did
not change Hes5 expression (Fig. 5D), arguing against
Hes5 as a mediator of neurofibromin-controlled multili-
neage differentiation. Similar results were observed in
Nf1-deficient NSCs treated with the SIS3 Smad3 pharma-
cological inhibitor (Supplemental Fig. S5A,B; Jinnin et al.
2006). Collectively, these results support a mechanism by
which neurofibromin/MEK control of astrocyte and neu-
ron differentiation operates in a Smad3/Jagged1/Hes1-de-
pendent manner.
Neurofibromin regulation of Smad3 function could op-
erate at the level of transcription, protein degradation, or
phosphorylation (Massague et al. 2005). While neurofibro-
min loss results in increasedSmad3levels, subcellular frac-
tionation revealed an enrichment of Smad3 in the nucleus
of Nf1−/− NSCs (34%) relative to wild-type NSCs (8%)
(Supplemental Fig. S5C). However, themechanismunder-
lying this increase in Smad3 expression was not the result
of increasedSmad3RNAlevels (qRT–PCR) (Supplemental
Fig. S5D) or degradationmediated by increased SCF/ROC1
and GSK3-β binding (Fukuchi et al. 2001; Guo et al. 2008).
Whereas Smad3 physically interacted with GSK3-β, but
not with SCF/ROC1 (Supplemental Fig. S5E), neurofibro-
min lossorMEKinhibition (PD901treatment)hadnoeffect
on Smad3 andGSK3-β binding, as assessed by immunopre-
cipitation. Finally, MEK-dependent Smad3 regulation was
not dependent on TGFβ-induced phosphorylation, as
Smad3-Ser423/425 phosphorylation was similar in wild-
type andNf1−/−NSCs (Supplemental Fig. S5F) and did not
involve phosphorylation at the best-characterized ERK
phosphorylation site (Ser208) (Supplemental Fig. S5F). Fu-
ture studies will be required to identify themechanism re-
sponsible for neurofibromin regulation of Smad3 levels.
Taken together, our findings establish that neurofibro-
min control of NSC function involves the selective use of
distinct RAS effector pathways. In this regard, RAS activa-
tion is critical for both neurofibromin-regulated NSC pro-
liferation and multilineage differentiation such that
inhibition using the nonselective RAS inhibitor (lovastat-
in) (Li et al. 2005) restored bothNf1-deficient NSC growth
and multilineage differentiation to wild-type levels (Sup-
plemental Fig. S5G–I). However, whereas neurofibromin
control of neuron and astrocyte differentiation requires
Smad3 regulation of Hes1, the mechanism underlying
Smad3-mediatedoligodendrocytedifferentiation likely in-
volves other transcription factors. In this manner, Olig-1
andOlig-2havebeen identifiedasessential factors for spec-
ifying oligodendrogliogenesis (Lu et al. 2000; Takebayashi
et al. 2002).Consistentwith recent findingsdemonstrating
that Olig1 is not essential for oligodendrocyte develop-
ment in mice (Paes de Faria et al. 2014), MEK inhibition
(PD901) reduced the increased Olig2, but not Olig1,
mRNA and protein expression in Nf1-deficient NSCs
(Fig. 5F). Moreover, the elevated Olig2 expression in Nf1-
deficient NSCs was decreased following Smad3 genetic
(Fig. 5G,H) or pharmacologic (Supplemental Fig. S5J) inhi-
bition. These findings suggest a model in which neurofi-
bromin control of NSC multilineage differentiation
involves distinct transcriptional programs:Neuron and as-
trocyte differentiation requires MEK/Smad3-dependent
Hes1 induction, whereas MEK/Smad3-dependent oligo-
dendrocytedifferentiation involvesOlig2 function (Fig. 5I).
Coupled with observations that other RAS downstream
pathways have cell type-specific functions (neurons vs. as-
trocytes) relevant to brain cell function (Hegedus et al.
2007;Anastasaki andGutmann2014), the observations re-
ported here establish that differential use of distinct RAS
effector signaling pathways can govern separable cellular
functions even within the same cell type, further under-
scoring the importance of cellular context in interpreting
the impact of genetic mutations on brain function.
Materials and methods
Mice
BLBP-Cre;Nf1flox/wt transgenic mice were crossed withNf1flox/flox mice to
generate BLBP-Cre; Nf1flox/flox (conditional knockout) mice. Nf1flox/flox
mice were used as wild-type controls. All strains were maintained on a
C57BL/6 background and used in accordance with an approved animal
studies protocol at Washington University.
Primary NSC analysis
TVZ NSCs were established from the TVZ of P1 Nf1flox/flox mouse pups
and analyzed as previously described (Lee et al. 2010). Retroviral and len-
tivirus (Supplemental Table 1) transduction was performed for overexpres-
sion and knockdown studies, respectively. All experiments were
performed at least three times using primary NSCs generated from inde-
pendent litters.
Western blotting
Western blotting was performed as previously reported (Lee et al. 2010) us-
ing primary antibodies (SupplementalTable 2) andwas quantified by densi-
tometry using a chemiluminescence imaging system (UVP). Each
experiment was performed at least three times, and representative blots
are presented.
Immunostaining
Paraffin or frozen sections were processed (Dasgupta and Gutmann 2005)
prior to staining with the appropriate antibodies. The percentage of Ki67+
cells lining the TVZwas quantified as previously reported (Lee et al. 2012).
Pharmacologic inhibition studies
Neurospheres were trypsinized into single cells, and 5 × 105 cells per well
were plated onto ultralow-binding 60-mm plates. Cells were treated with
specific inhibitors for 4–5 d. PD901 (5 mg/kg/day; Selleck), BKM120
(30 mg/kg; Selleck), or matched vehicle (0.5% hydroxypropyl methycellu-
losewith 0.2%Tween 80 [Sigma-Aldrich] or 10/90 [v/v] N-methyl-2-pyrro-
lidone [NMO]/PEG300, respectively) was injected intraperitoneally into
pregnant females from E15 to E18. Postnatal PD901 or NVP-BKM120 ad-
ministration to lactating females (P0.5–P18) was achieved by oral gavage,
and the mice were perfused at P18.
Real-time qRT–PCR
Real-time qRT–PCR was performed as previously described (Yeh et al.
2009) with specific primers (Supplemental Table 3), and ΔΔCT values
were calculated using H3f3a as an internal control.
Statistical analysis
Each experiment was performed with samples from at least three indepen-
dent groups. Statistical significance was set at P < 0.05 using the Student’s
t-test.
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